Papers/PMID:38773199
Glycine by enteral route does not improve major clinical outcomes in severe COVID-19: a randomized clinical pilot trial.
Scientific reports2024The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
glycine — no detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There were no differences in mortality (glycine group, 63.6% vs control group, 52.2%, p = 0.60) nor in any other major outcome.”
Quoted verbatim from Glycine by enteral route does not improve major clinical outcomes in severe COVID-19: a randomized clinical pilot trial.. - Study
- RCT
- Dose
- 0.5 g/kg/day glycine by the enteral route
- Population
- Inpatients with severe COVID-19 requiring mechanical ventilation; usual care in both arms, glycine added in the experimental arm; open label
Glycine by enteral route does not improve major clinical outcomes in severe COVID-19: a randomized clinical pilot trial.2024PMID:38773199Permalink